Bio-Path Holdings
  • About Bio-Path
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us
  • About Bio-Path
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us
November 8, 2022

Webcast Link to Third Quarter 2022 Earnings Financial Results Conference Call – Tuesday November 15, 2022 at 8:30 a.m. ET

September 6, 2022

Webcast link to H.C. Wainwright 24th Annual Global Investment Conference – Monday, September 12, 2022 at 7:00 am ET

August 17, 2022

H.C. Wainwright & Co. – August 17, 2022 – Article

August 13, 2022

Webcast Link to Second Quarter 2022 Earnings Financial Results Conference Call – Tuesday, August 16, 2022 at 8:30 a.m. ET

August 12, 2022

Corporate Presentation May 2022

May 10, 2022

Webcast Link to First Quarter 2022 Earnings Financial Results Conference Call – Tuesday, May 17, 2022 at 8:30 a.m. ET

April 14, 2022

BP1003 AACR 2022 Abstract

March 4, 2022

Webcast Link to 2021 Full Year Earnings Financial Results Conference Call – Friday, March 11, 2022 at 8:30 a.m. ET

February 1, 2022

Making Sense of Antisense Oligonucleotide Therapeutics Targeting Bcl-2.

February 1, 2022

The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery

December 21, 2020

Annual Shareholders Presentation Slides – December 2020

December 6, 2019

STONEGATE Capital Partners December 4, 2019 Report

December 2, 2019

H.C. Wainwright / BPTH: Safety Testing of Phase 2 AML Trial Completed; Financing Closed; Reiterate Buy; Adjusting PT to $25

January 31, 2019

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) – January 2019

August 23, 2018

Stonegate Capital Partners Research Report – August 2018

March 6, 2018

BP1001 phase I-Ib protocol

March 2, 2018

Drug Development and Delivery Published Article: DNA THERAPEUTICS – DNAbilize-ING Antisense

June 9, 2017

Published Article: Evolution of Antisense Oligonucleotides in Oncology

June 28, 2016

Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01

April 7, 2016

OncLive interview with Dr. Cortes on BP-100.01 in Patients with Relapsed/Refractory AML

April 5, 2016

Bio-Path Hopes to Blaze Profitable Path With Antisense Drugs – January 2016

Bio-Path Holdings

All Rights Reserved

Office:

4710 Bellaire Blvd, Suite 210
Bellaire, TX 77401

T: (832) 742-1357

R&D:

5455 Dashwood Street, Suite 300
Bellaire, TX 77401

T: (832) 742-1357

logo
  • About Bio-Path
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us